LESLIE CITROME: "Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil", EXPERT REVIEW OF CLINICAL PHARMACOLOGY 20141101 EXPERT REVIEWS LTD. GBR, vol. 9, no. 2, 19 December 2015 (2015-12-19), UK, pages 169 - 186, XP055398416, ISSN: 1751-2433, DOI: 10.1586/17512433.2016.1121809 (B1)

MARJIE L. HARD ET AL: "Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia :", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY., vol. 38, no. 5, 1 October 2018 (2018-10-01), US, pages 435 - 441, XP055590436, ISSN: 0271-0749, DOI: 10.1097/JCP.0000000000000921 (B1)

WANG X ET AL: "P.533 The two-injection start of aripiprazole once-monthly provides rapid attainment of therapeutic concentrations without the need for 14-day oral tablet supplementation", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SIENCE PUBLISHERS BV , AMSTERDAM, NL, vol. 40, 1 November 2020 (2020-11-01), XP086353709, ISSN: 0924-977X, [retrieved on 20201117], DOI: 10.1016/J.EURONEURO.2020.09.388 (B1)

US-A1- 2015 087 654 (B1)

US-A1- 2019 099 494 (B1)

MARJIE L. HARD ET AL: "Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model", CNS DRUGS, vol. 31, no. 7, 8 June 2017 (2017-06-08), AUCKLAND, NZ, pages 617 - 624, XP055590498, ISSN: 1172-7047, DOI: 10.1007/s40263-017-0447-7 (B1)